115 PREVALENCE OF NEUROPATHIC PAIN SYMPTOMS IN PATIENTS WITH CANCER BONE PAIN REFERRED FOR PALLIATIVE RADIOTHERAPY

2009 ◽  
Vol 92 ◽  
pp. S37
Author(s):  
M. Kerba ◽  
J.S. Wu ◽  
Q. Duan ◽  
N. Hagen ◽  
M. Bennett
Keyword(s):  
Neuropathic Pain ◽  
Bone Pain ◽  
Palliative Radiotherapy ◽  
Patients With Cancer ◽  
Pain Symptoms

scholarly journals The Palliative Radiotherapy and Inflammation Study (PRAIS) - protocol for a longitudinal observational multicenter study on patients with cancer induced bone pain

2018 ◽  
Vol 17 (1) ◽  
Author(s):  
Ragnhild Habberstad ◽  
Trude Camilla Salvesen Frøseth ◽  
Nina Aass ◽  
Tatiana Abramova ◽  
Theo Baas ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Bone Pain ◽  
Palliative Radiotherapy ◽  
Patients With Cancer

scholarly journals Incidence, Aetiology, and Associated Fracture Patterns of Infraorbital Nerve Injuries Following Zygomaticomaxillary Complex Fractures: A Retrospective Analysis of 272 Patients

2021 ◽  
pp. 194338752110225
Author(s):  
Kathia Dubron ◽  
Maarten Verbist ◽  
Eman Shaheen ◽  
Titiaan Jacob Dormaar ◽  
Reinhilde Jacobs ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Interpersonal Violence ◽  
Fracture Line ◽  
Infraorbital Nerve ◽  
Type B ◽  
Treatment Methods ◽  
Infraorbital Canal ◽  
Pain Symptoms ◽  
Fracture Types ◽  
Zygomaticomaxillary Complex

Study Design: Retrospective study. Objective: Zygomaticomaxillary complex (ZMC) fractures are common facial injuries with heterogeneity regarding aetiologies, fracture types, infraorbital nerve (ION) involvement, and treatment methods. The aim of this study was to identify associations between aetiologies, fracture types, and neurological complications. Additionally, treatment methods and recovery time were investigated. Methods: Medical files of 272 patients with unilateral and bilateral ZMC fractures were reviewed, whose cases were managed from January 2014 to January 2019 at the Department of Oral and Maxillofacial Surgery, University hospitals Leuven, Belgium. History of ION sensory dysfunction and facial nerve motoric dysfunction were noted during follow-up. Results: ION hypoaesthesia incidence was 37.3%, with the main causes being fall accidents, road traffic accidents, and interpersonal violence. Significant predictors of ION hypoaesthesia were Zingg type B fractures ( P = 0.003), fracture line course through the infraorbital canal ( P < .001), orbital floor fracture ( P < 0.001), and ZMC dislocation or mobility ( P = 0.001). Conclusion: Of all ZMC fractures, 37.3% exhibited ION hypoaesthesia. Only ZMC Zingg type B fractures (74.0%) were significantly more associated with ION hypoaesthesia. ION hypoesthesia was more likely (OR = 2.707) when the fracture line course ran through the infraorbital canal, and was less dependent on the degree of displacement. Neuropathic pain symptoms developed after ZMC fractures in 2.2% patients, posing a treatment challenge. Neuropathic pain symptoms were slightly more common among women, and were associated only with type B or C fractures. No other parameters were found to predict the outcome of this post-traumatic neuropathic pain condition.

Neuropathic pain symptoms in inflammatory hand osteoarthritis (OA) lower quality of life and may require another approach than anti-inflammatory treatment

2021 ◽  
Vol 29 ◽  
pp. S237-S238
Author(s):  
C. van der Meulen ◽  
L.A. van de Stadt ◽  
F.P. Kroon ◽  
M.C. Kortekaas ◽  
A. Boonen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Neuropathic Pain ◽  
Hand Osteoarthritis ◽  
Anti Inflammatory ◽  
Pain Symptoms

NMDA Antagonist Peptide Supplementation Enhances Pain Alleviation by Adrenal Medullary Transplants

2005 ◽  
Vol 14 (4) ◽  
pp. 203-211 ◽  
Author(s):  
Farinaz Nasirinezhad ◽  
Jacqueline Sagen
Keyword(s):  
Neuropathic Pain ◽  
Animal Models ◽  
Striated Muscle ◽  
Thermal Hyperalgesia ◽  
Nmda Antagonist ◽  
Nmda Receptor Antagonist ◽  
Intraplantar Injection ◽  
Amino Acid Peptide ◽  
Spinal Subarachnoid Space ◽  
Pain Symptoms

Spinal transplantation of adrenal medullary chromaffin cells has been shown to decrease pain responses in several animal models. Improved potency may be possible by engineering cells to produce greater levels of naturally derived analgesics. As an initial screen for potential candidates, adrenal medullary transplants were evaluated in combination with exogenously administered neuropeptides in rodent pain models. Histogranin is a 15-amino acid peptide that exhibits NMDA receptor antagonist activity. The stable derivative [Ser1]histogranin (SHG) can attenuate pain symptoms in some animal models. The formalin model for neurogenic inflammatory pain and the chronic constriction injury (CCI) model for neuropathic pain were used to evaluate the combined effects of chromaffin cell transplantation and intrathecal (IT) SHG injections. Animals were implanted with either adrenal medullary or control striated muscle tissue in the spinal subarachnoid space. For evaluation of formalin responses, animals were pretreated with SHG (0.5, 1.0, 3.0 μg) followed by an intraplantar injection of formalin, and flinching responses were quantified. Pretreatment with SHG had no significant effect on flinching behavior in control animals at lower doses, with incomplete attenuation only at the highest dose. In contrast, 0.5 μg SHG significantly reduced flinching responses in animals with adrenal medullary transplants, and 1.0 μg nearly completely eliminated flinching in these animals in the tonic phase. For evaluation of effects on neuropathic pain, animals received transplants 1 week following CCI, and were tested for thermal and mechanical hyperalgesia and cold allodynia before and following SHG treatment. The addition of low doses of SHG nearly completely eliminated neuropathic pain symptoms in adrenal medullary transplanted animals, while in control transplanted animals only thermal hyperalgesia was attenuated, at the highest dose of SHG. These results suggest that SHG can augment adrenal medullary transplants, and the combination may result in improved effectiveness and range in the treatment of chronic pain syndromes.

Topiramate in the Treatment of Neuropathic Pain in Patients with Cancer

2007 ◽  
Vol 4 (4) ◽  
pp. 241-246 ◽  
Author(s):  
Edmond A. Bendaly ◽  
Carol A. Jordan ◽  
Sandra S. Staehler ◽  
Daniel A. Rushing
Keyword(s):  
Neuropathic Pain ◽  
Patients With Cancer

Adjuvant analgesics

2015 ◽  
Author(s):  
David Lussier ◽  
Russell K. Portenoy
Keyword(s):  
Neuropathic Pain ◽  
Clinical Experience ◽  
Bone Pain ◽  
Scientific Evidence ◽  
Opioid Therapy ◽  
Limited Data ◽  
First Line ◽  
Serious Illness ◽  
Dosing Strategies ◽  
Sequential Trials

In the management of pain associated with serious illness, ‘adjuvant analgesics’ usually are administered in concert with opioid therapy in an effort to improve outcomes when an opioid does not provide satisfactory relief with tolerable side effects. They may be divided into categories, including multipurpose drugs, and drugs used selectively for neuropathic pain, bone pain, pain due to bowel obstruction, or musculoskeletal pain. These drugs are selected for a trial based on limited data available and clinical experience; sequential trials may be undertaken when pain is refractory. Multipurpose drugs may be considered for any type of pain. The most useful include corticosteroids and analgesic antidepressants. For neuropathic pain, conventional first-line agents are gabapentinoids, analgesic antidepressants, and corticosteroids. Corticosteroids and bisphosphonates, are used commonly for bone pain. The indications and dosing strategies for these drugs are evolving as scientific evidence and clinical experience accumulate.

scholarly journals Capsaicin in the Treatment of Refractory Neuropathic Pain after Mastectomy Surgery: A Case Report

2020 ◽  
Vol 13 (2) ◽  
pp. 997-1001
Author(s):  
Lilit Flöther ◽  
David Avila-Castillo ◽  
Anna-Maria Burgdorff ◽  
Ralf Benndorf
Keyword(s):  
Neuropathic Pain ◽  
Pain Relief ◽  
Anxiety And Depression ◽  
Pain Medications ◽  
Oral Pain ◽  
Patient Reported ◽  
History Of ◽  
Oral Pain Medication ◽  
Pain Symptoms

A 62-year-old female patient with a history of mastectomy surgery and sentinel lymphadenectomy in the context of breast cancer therapy was referred to our clinic for the treatment of refractory neuropathic pain. She reported a complex set of symptoms including burning and electrical-like sensations as well as profound hyperesthesia, hyperalgesia, and allodynia. The symptoms persisted chronically over months with a strong intensity and did not sufficiently respond to oral pain medication and co-analgetics, that is, tapentadol and pregabalin. As the patient could hardly move her right upper arm due to the pain, the quality of life was greatly reduced. In addition, the patient reported pain-related anxiety and depression. Therefore, a therapy with capsaicin 8% patch was initiated. Treatment with capsaicin 8% led to pain relief without tolerance development and improved flexibility in the affected body area. Despite significant pain relief, previous oral pain medications (tapentadol, pregabalin) as well as the anti-depressant amitriptyline were maintained to fully resolve pain symptoms, anxiety, and depression. In conclusion, capsaicin 8% may represent an effective therapeutic alternative for patients suffering from refractory neuropathic pain.

Communication Between Primary Care Physicians and Radiation Oncologists Regarding Patients With Cancer Treated With Palliative Radiotherapy

2000 ◽  
Vol 18 (15) ◽  
pp. 2902-2907 ◽  
Author(s):  
Elizabeth A. Barnes ◽  
John Hanson ◽  
Catherine M. Neumann ◽  
Cheryl L. Nekolaichuk ◽  
Eduardo Bruera
Keyword(s):  
Primary Care ◽  
Support Services ◽  
Primary Care Physicians ◽  
Information Needs ◽  
Palliative Radiotherapy ◽  
Patient Support ◽  
Patients With Cancer ◽  
Radiation Oncologists ◽  
Actual Content

PURPOSE: The purpose of this study was to assess the satisfaction and information needs of primary care physicians (PCPs) regarding communication with radiation oncologists (ROs), with respect to patients who receive palliative radiotherapy (RT). A selected objective was to evaluate the agreement between PCPs’ expectations and the content of the RO letter sent after completion of RT. PCPs’ knowledge of the role of palliative RT and their awareness of available patient support services were also determined. METHODS: The PCPs of patients discharged from the Cross Cancer Institute after receiving palliative RT were surveyed using a mail-out questionnaire. Questions regarding communication, RT knowledge, and awareness of support services were asked. The corresponding RO letter was reviewed. RESULTS: A total of 148 PCPs were identified and were mailed questionnaires, with 114 (77%) responding. Overall, 80% (87 of 109) of PCPs found the RO letter to be useful in patient management. However, there was poor (< 53%) agreement between PCPs’ expectations and the actual content of the RO letter. Knowledge of the indications and effectiveness of palliative RT was limited, with PCPs obtaining a median score of 4 of a possible 8. Only 27% (31 of 114) of PCPs were aware of all five of the patient support services listed. CONCLUSION: Results show that although the majority of PCPs found the RO letter useful, they believed that the letter lacked important information while containing unnecessary details. Communication between PCPs and ROs needs improvement, especially considering that PCPs seem to have limited knowledge of palliative RT.

Sign in / Sign up

Export Citation Format

Share Document